Socioeconomic and demographic factors impact surgical outcomes in upper extremity soft tissue sarcomas, affecting amputation rates and overall survival. Hispanic/Latino patients presented with larger ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

This retrospective cohort study of limb-sparing eSTS resections integrated clinical variables and radiomic features, including eSTS and limb dimensions. Target outcomes included surgical site ...

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the extremity, a randomized trial showed. In patients with mostly undifferentiated ...

Patients in this analysis were treated between 2007 and 2020 and could have received radiotherapy either before or after surgery for soft tissue sarcoma (STS). STS is rare, in that it accounts for a ...

Surgery is the primary treatment for soft tissue sarcoma. It aims to remove cancerous tumors from tissues like muscle and fat. The type of surgery needed depends on the tumor’s characteristics, ...

Please provide your email address to receive an email when new articles are posted on . The addition of pembrolizumab to radiation and surgery reduced relapse risk by 43%. Results showed no ...

Please provide your email address to receive an email when new articles are posted on . Negative pressure wound therapy for soft tissue sarcoma yielded similar pain and patient-reported outcome ...

In a retrospective analysis, moderately hypofractionated definitive radiotherapy (MHDRT) achieved 1-year local control rates of more than 90% for soft tissue sarcomas (STS) and 100% for chordomas in ...

Soft tissue sarcomas are a rare group of cancers that develop in soft tissue. They can develop almost anywhere in your body, including in your hip, thigh, and groin. Soft tissue sarcomas are rare ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results ...